| __timestamp | Alkermes plc | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7753000 | 46425000 |
| Thursday, January 1, 2015 | 4019000 | 81491000 |
| Friday, January 1, 2016 | 2301000 | 94291000 |
| Sunday, January 1, 2017 | 7232000 | 121827000 |
| Monday, January 1, 2018 | 68895000 | 160524000 |
| Tuesday, January 1, 2019 | 52816000 | 200000000 |
| Wednesday, January 1, 2020 | 1946000 | 275000000 |
| Friday, January 1, 2021 | 1020000 | 328100000 |
| Saturday, January 1, 2022 | 393842000 | 463800000 |
| Sunday, January 1, 2023 | 270806000 | 565000000 |
| Monday, January 1, 2024 | 245326000 | 731100000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Alkermes plc have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Neurocrine Biosciences increased its R&D expenses by over 1,100%, peaking in 2023 with a staggering 565% increase from its 2014 levels. In contrast, Alkermes plc's R&D spending showed more volatility, with a significant spike in 2022, reaching nearly 400% of its 2014 expenditure. This divergence highlights Neurocrine's consistent growth strategy, while Alkermes appears to adopt a more fluctuating approach. As the biotech industry continues to evolve, these spending patterns may offer insights into each company's future innovation trajectory and market positioning. Understanding these trends is crucial for investors and stakeholders aiming to gauge the potential of these biotech giants.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Neurocrine Biosciences, Inc. or CymaBay Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Research and Development: Comparing Key Metrics for Alkermes plc and Protagonist Therapeutics, Inc.
Alkermes plc or MorphoSys AG: Who Invests More in Innovation?
Alkermes plc or Xencor, Inc.: Who Invests More in Innovation?